We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
In most countries, Global Fund grants are highly commoditized as the largest proportion of the grant investments are used to pay for health and non-health commodities. This means that the supply chain, together with procurement, absorb a significant proportion of grant funds. The extent to which countries handle these two areas is critical to achieving the Global Fund’s mission. As…
The role of national central procurement agencies National central procurement agencies for essential drugs fulfill a public service with a social purpose, in accordance with their national pharmaceutical policies. Those institutions, called CAMEG (La Centrale d’Achat des Médicaments Essentiels Génériques et des consommables médicaux) for Central Agencies for Essential and Generic Medicines, are autonomous government institutions that purchase quality medications, laboratory reagents…
“There is often an asymmetry between the high level of accountability for impact that the Global Fund is generally held to and the sometimes low level of control that the organization has on many of the factors that drive such impact.” These were the words of the Office of the Inspector General (OIG) in its 2017 Annual Report which was…
Subscribe to our newsletter below and never miss the latest updates.
Subscribe to our weekly newsletter below.
How can the Global Fund finance innovation to improve health product supply chains in resource-limited settings?
Dr Alassane Ba and Dr Karl Hounmenou